Erythropoietin and Radiotherapy: A Dangerous Combinations?

Strahlentherapie und Onkologie

Volumn 180, Issue 3, 2004, Pages 133-135

  Dunst, Jürgen ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; ERYTHROPOIETIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; CYTOKINE PRODUCTION; DATA ANALYSIS; DRUG EFFECT; DRUG RESEARCH; EDITORIAL; EXPERIMENTAL DESIGN; HUMAN; HYPOXIA; PEER REVIEW; PROGNOSIS; RADIATION RESPONSE; TISSUE OXYGENATION;

ANEMIA; CELL HYPOXIA; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DISEASE MODELS, ANIMAL; DOSE FRACTIONATION; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEAD AND NECK NEOPLASMS; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; META-ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PELVIC NEOPLASMS; PLACEBOS; PROGNOSIS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 1542319911     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (37)

1. Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003;162:1789-806.
2. Batra S, Perelman N, Lori R, et al. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003;83:1477-87.
3. Becker A, Stadler P, Lavey R, et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2000;46:459-66.
4. Berdel WE, Oberberg D, Reufi B, et al. Studies on the role of recombinant erythropoietin in the growth regulation of human non-hematopoietic cells in vitro. Ann Hematol 1991;63:5-8.
5. Blohmer JU, Minckwitz G von, Paepke S, et al. Sequential adjuvant chemoradiotherapy with vs. without erythropoietin for patients with high-risk cervical cancer - second analysis of a prospective, randomized, open and controlled AGO- and NOGGO-Intergroup study. Proc Am Soc Clin Oncol 2002;21:206a.
6. Bush RS. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 1986;12:2047-50.
7. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-21.
8. Cerami A. Beyond erythropoiesis: novel applications for recombinant erythropoietin. Semin Hematol 2001;38;Suppl 7:33-9.
9. Cerami A, Brins M, Ghezzi P, et al. Neuroprotective properties of epoietin alfa. Nephrol Dial Transplant 2002;17:Suppl 1:8-12.
10. Cheung WK, Natarajan J, Sanders M, et al. Comparative pharmacokinetics, safety, and tolerability after subcutaneous administration of recombinant human erythropoietin formulated with different stabilizers. Biopharm Drug Dispos 2000;21:211-9.
11. Dunst J, Becker A, Lautenschlager C, et al. Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther Onkol 2002;178:436-41.
12. Dunst J, Kuhnt T, Strauss G, et al. Anemia in cervical cancers: prognostic impact, patterns of relapse and association with angiogenesis. Int J Radiat Oncol Biol Phys 2003;56:778-87.
13. Frommhold H, Guttenberger R, Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol 1998;174:Suppl IV:31-4.
14. Fyles AW, Milosevic M, Pintilie M, et al. Anemia, hypoxia and transfusion in patients with cervical cancer: a review. Radiother Oncol 2000;57:13-9.
15. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823-33.
16. Grau C, Overgaard J. Significance of hemoglobin concentrations for treatment outcome. In: Molls M, Vaupel P, eds. Blood perfusion and microenvironment of human tumors. Implications for clinical radiooncology. Berlin: Springer, 1998:101-12.
17. Grogan M, Thomas GM, Melamed I, et al. The importance of maintaining high hemoglobin levels during radiation treatment of carcinoma of the cervix. Cancer 1999;86:1531-6.
18. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
19. Hoeckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biological and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
20. Kelleher DK, Matthiensen U, Thews O, et al. Tumor oxygenation in anemic rats: effects of erythropoietin treatment versus red blood cell transfusion. Acta Oncol 1995;34:379-84.
21. Kelleher DK, Matthiensen U, Thews O, et al. Blood flow, oxygenation and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 1996;56:4728-34.
22. Lutterbach J, Sauerbrei W, Guttenberger R. Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlenther Onkol 2003;179:8-15.
23. Nowrousian MR. Pathophysiology of cancer-related anemia. In: Nowrousian MR, ed. Recombinant human erythropoietin (rhEPO) in clinical oncology. Wien-New York: Springer, 2002.
24. Rofstad EK, Sundfor K, Lyng H, et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastases. Br J Cancer 2000;83:354-9.
25. Rosti V, Pedrazzoli P, Ponchio L, et al. Effect of recombinant human erythropoietin on the hematopoietic and nonhematopoietic malignant cell growth in vitro. Haematologica 1993;78:208-12.
26. Schaefer U, Micke O, Muller SB, et al. Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 2003;179:527-34.
27. Selzer E, Wachek V, Kodym R, et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000;10:421-6.
28. Stueben G, Thews O, Poettgen C, et al. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001;127:346-50.
29. Stueben G, Thews O, Poettgen C, et al. Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation. Strahlenther Onkol 2003;179:620-5.
30. Tarnawski R, Skladowski K, Maciejewski B. Prognostic value of hemoglobin concentration in radiotherapy for cancer of the supraglottic larynx. Int J Radiat Oncol Biol Phys 1997;38:1007-11.
31. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61:1358-61.
32. Thews O, König R, Kelleher DK, et al. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998;78:752-66.
33. Van Acht MJ, Hermans J, Boks DE, et al. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol 1992;23:229-23.
34. Vaupel P, Thews O, Mayer A, et al. Oxygenation status of gynecological tumors: what is the optimal hemoglobin Level? Strahlenther Onkol 2002;178:727-31.
35. Wagner W, Hermann R, Hartlapp J, et al. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther Onkol 2000;176:73-80.
36. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000;58:647-57.
37. Westphal G, Niederberger L, Blum C, et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002;88:150-9.